


Official global newsroom account for Biogen, a leading biotech company pioneering innovative science since 1978. Community guidelines: bit.ly/1MZocKs





#News: At the American College of Rheumatology (ACR) Convergence we announced data for an investigational therapy for people living with systemic lupus erythematosus (SLE). Read more: bit.ly/4BW2dTu



We're heading to #BIOEurope! Join our panel discussion to hear insights on advancing innovation, strategic partnerships, and the shifting global landscape. Learn about our partnering opportunities across the globe: spr.ly/6010BHFy1o




#News: Today we reported our Q3 results, demonstrating that Biogen has returned to growth. Read more: bit.ly/4jKNtQy Forward-looking statements: biogen.com/forward-looking-s… #Earnings $BIIB

At @ASNKidney #KidneyWk we’re presenting the latest data across our kidney disease portfolio. Stop by booth #588 and join us at our medical symposiums to learn about our ongoing work to address the unmet needs of this community.

#News: We’re attending @ASNKidney #KidneyWk to share data from our nephrology portfolio. Read more about our upcoming presentations: spr.ly/6012BHR9MG

#News: Biogen New Ventures is proud to participate in the Series A financing of Estuary Biotherapeutics, a company pioneering targeted gene therapies for autosomal dominant polycystic kidney disease (ADPKD). Learn more: spr.ly/6012BHzBe4

#News: Biogen New Ventures is proud to participate in Altay Therapeutics' Series A financing to support the development of an investigational oral therapy for facioscapulohumeral muscular dystrophy (FSHD). Learn more: bit.ly/4s2mBgW